As the digital medium poses new threats to brand equity and public safety for pharma, what can drugmakers do to better balance its essential communications benefits with the risks?
Alex Goldenberg
Advertisement
Director of Intelligence, Network Contagion Research Institute
Articles by Alex Goldenberg
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Pharma Collaborations Focused on Advancing Antibody-Drug Conjugates and Delivering Treatments for Autoimmune Diseases
2
What Impact will TrumpRx and Other DTC Programs Have on Drug Availability?
3
Roundup: Biopharmaceutical Industry Activity Accelerates with Focus on Rare Diseases and Novel Therapies
4
Roundup: Biopharma Funding Rounds Advance Clinical Development of Novel Therapy and Treatment Solutions
5
